Katie Ellias

Director/Board Member at SAB BIOTHERAPEUTICS, INC.

47 year

Health Technology

Finance

Consumer Services

Profile

Katie Ellias is currently an Independent Director at SAB Biotherapeutics, Inc. since 2023.
Former roles include Managing Director at A Breakthrough T1D Venture LLC from 2018 to 2024, Director at Capillary Biomedical LLC from 2019 to 2022, Investment Director at Endeavour Vision SA from 2016 to 2017, Consultant at Tech Health Experts from 2017 to 2018, and Principal at Sofinnova Partners SAS from 2011 to 2016.
Also served as Director at Veralox Therapeutics, Inc., I2o Therapeutics, Inc., and DiogenX SAS. Education includes an undergraduate degree from Yale University in 2000 and an MBA from The Wharton School of the University of Pennsylvania in 2006.

Katie Ellias active positions

Companies	Position	Start
SAB BIOTHERAPEUTICS, INC.	Director/Board Member	2023-11-19

All active positions of Katie Ellias

Former positions of Katie Ellias

Companies	Position	End
JDRF T1D Fund JDRF T1D Fund Investment ManagersFinance T1D Fund invests in companies located across the globe. The firm focuses on health technology sector. It participates in early stage capital requirements.	Private Equity Investor	2024-10-31
Capillary Biomedical LLC Capillary Biomedical LLC Medical SpecialtiesHealth Technology Develops medical devices for diabetes management	Director/Board Member	2022-06-30
Tech Health Experts Tech Health Experts Information Technology ServicesTechnology Services Provides technical support services	Consultant / Advisor	2018-07-29
Endeavour Vision SA Endeavour Vision SA Investment ManagersFinance EV develops a long-term investment strategy with their entrepreneurs. Their investment objective is to grow firms and to create a market leader in a new field. They focus on developing businesses active in industries including information technology, biotech, medtech and cleantech. They concentrate on various stages such as early to expansion-stage as well as spin-offs and restarts. Their geographic focus is pan-European. Specifically, their technology-sector investments are concentrated in Norway, Sweden, Finland, UK, Ireland, Germany, Switzerland, France, Italy and Portugal. Beyond these countries, they also consider taking a co-lead or a syndicate role. For their life sciences investments, they primarily target Switzerland, France and Germany. Four key investment criteria they consider before investment are hyper-growth market potential, world-class technology, capital efficiency and ambitious management team. EV's preferred role is to be lead investor or possibly co-lead. They also consider being syndicate partner on some occasions. EV's investment horizon is generally 10 years, with that timeframe extended for firms in hyper-growth stage. On average, their investments typically take five years to mature. The majority of their exits are through a listing in one of the main markets while many of the VC-backed firms are acquired.	Private Equity Investor	2017-09-29
Sofinnova Partners SAS Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners invests in companies located in the United States, France and Europe. The firm targets companies operating in the fields of life sciences and technology sectors. It provides financing for seed and early stage capital requirements.	Private Equity Investor	2016-11-29

See the detail of Katie Ellias's experience

Training of Katie Ellias

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Katie Ellias's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	11
Capillary Biomedical LLC Capillary Biomedical LLC Medical SpecialtiesHealth Technology Develops medical devices for diabetes management	Health Technology
Sofinnova Partners SAS Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners invests in companies located in the United States, France and Europe. The firm targets companies operating in the fields of life sciences and technology sectors. It provides financing for seed and early stage capital requirements.	Finance
Yale University Yale University Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Endeavour Vision SA Endeavour Vision SA Investment ManagersFinance EV develops a long-term investment strategy with their entrepreneurs. Their investment objective is to grow firms and to create a market leader in a new field. They focus on developing businesses active in industries including information technology, biotech, medtech and cleantech. They concentrate on various stages such as early to expansion-stage as well as spin-offs and restarts. Their geographic focus is pan-European. Specifically, their technology-sector investments are concentrated in Norway, Sweden, Finland, UK, Ireland, Germany, Switzerland, France, Italy and Portugal. Beyond these countries, they also consider taking a co-lead or a syndicate role. For their life sciences investments, they primarily target Switzerland, France and Germany. Four key investment criteria they consider before investment are hyper-growth market potential, world-class technology, capital efficiency and ambitious management team. EV's preferred role is to be lead investor or possibly co-lead. They also consider being syndicate partner on some occasions. EV's investment horizon is generally 10 years, with that timeframe extended for firms in hyper-growth stage. On average, their investments typically take five years to mature. The majority of their exits are through a listing in one of the main markets while many of the VC-backed firms are acquired.	Finance
The Wharton School of the University of Pennsylvania The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
JDRF T1D Fund JDRF T1D Fund Investment ManagersFinance T1D Fund invests in companies located across the globe. The firm focuses on health technology sector. It participates in early stage capital requirements.	Finance
Veralox Therapeutics, Inc. Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Provides drug discovery and development services for clinical stage company	Health Technology
I2o Therapeutics, Inc. I2o Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops injection pills for biological therapies	Health Technology
DiogenX SAS DiogenX SAS BiotechnologyHealth Technology Operates as preclinical stage biotech company, that engages in develops and research biologics therapeutics options for diabetic patients	Health Technology
Tech Health Experts Tech Health Experts Information Technology ServicesTechnology Services Provides technical support services	Technology Services
SAB Biotherapeutics, Inc. SAB Biotherapeutics, Inc. BiotechnologyHealth Technology Engages in advancing a new class of immunotherapies	Health Technology